- Home
- AUPH vs LILAK Comparison
AUPH vs LILAK Comparison
Compare AUPH & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- LILAK
- Stock Information
- Founded
- AUPH 1993
- LILAK 2017
- Country
- AUPH Canada
- LILAK Bermuda
- Employees
- AUPH N/A
- LILAK N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- LILAK Cable & Other Pay Television Services
- Sector
- AUPH Health Care
- LILAK Telecommunications
- Exchange
- AUPH Nasdaq
- LILAK Nasdaq
- Market Cap
- AUPH 999.8M
- LILAK 1.1B
- IPO Year
- AUPH 1999
- LILAK N/A
- Fundamental
- Price
- AUPH $7.85
- LILAK $5.06
- Analyst Decision
- AUPH Strong Buy
- LILAK Buy
- Analyst Count
- AUPH 2
- LILAK 3
- Target Price
- AUPH $11.50
- LILAK $10.27
- AVG Volume (30 Days)
- AUPH 1.1M
- LILAK 1.7M
- Earning Date
- AUPH 05-12-2025
- LILAK 05-07-2025
- Dividend Yield
- AUPH N/A
- LILAK N/A
- EPS Growth
- AUPH N/A
- LILAK N/A
- EPS
- AUPH 0.27
- LILAK N/A
- Revenue
- AUPH $247,295,000.00
- LILAK $4,441,000,000.00
- Revenue This Year
- AUPH $11.86
- LILAK $4.42
- Revenue Next Year
- AUPH $24.96
- LILAK $3.59
- P/E Ratio
- AUPH $29.71
- LILAK N/A
- Revenue Growth
- AUPH 29.20
- LILAK N/A
- 52 Week Low
- AUPH $4.98
- LILAK $5.10
- 52 Week High
- AUPH $10.67
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- AUPH 44.68
- LILAK 42.93
- Support Level
- AUPH $7.89
- LILAK $4.36
- Resistance Level
- AUPH $8.49
- LILAK $5.16
- Average True Range (ATR)
- AUPH 0.30
- LILAK 0.32
- MACD
- AUPH -0.02
- LILAK -0.02
- Stochastic Oscillator
- AUPH 36.95
- LILAK 57.64
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.